These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 33249467)

  • 1. Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial.
    Hohnloser SH; Camm AJ; Cappato R; Diener HC; Heidbüchel H; Mont L; Morillo CA; Lanz HJ; Rauer H; Reimitz PE; Smolnik R; Kautzner J
    Europace; 2021 Jan; 23(1):65-72. PubMed ID: 33249467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
    Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
    Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial.
    Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbüchel H; Mont L; Morillo CA; Abozguia K; Grimaldi M; Rauer H; Reimitz PE; Smolnik R; Mönninghoff C; Kautzner J
    Eur Heart J; 2019 Sep; 40(36):3013-3021. PubMed ID: 30976787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Periprocedural management of anticoagulation for atrial fibrillation catheter ablation in direct oral anticoagulant-treated patients.
    Martin AC; Lessire S; Leblanc I; Dincq AS; Philip I; Gouin-Thibault I; Godier A
    Clin Cardiol; 2018 May; 41(5):646-651. PubMed ID: 29532536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uninterrupted anticoagulation during catheter ablation for atrial fibrillation: no difference in major bleeding and stroke between direct oral anticoagulants and vitamin K antagonists in an updated meta-analysis of randomised controlled trials.
    Brockmeyer M; Lin Y; Parco C; Karathanos A; Krieger T; Schulze V; Heinen Y; Bejinariu A; Müller P; Makimoto H; Kelm M; Wolff G
    Acta Cardiol; 2021 May; 76(3):288-295. PubMed ID: 32056498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in activated clotting time and initial heparin dosage during atrial fibrillation ablation for patients with edoxaban compared with warfarin.
    Yamaji H; Murakami T; Hina K; Higashiya S; Kawamura H; Murakami M; Kamikawa S; Hirohata S; Kusachi S
    J Cardiovasc Electrophysiol; 2018 Jun; 29(6):835-843. PubMed ID: 29533476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants.
    Brinkmeier-Theofanopoulou M; Tzamalis P; Wehrkamp-Richter S; Radzewitz A; Merkel M; Schymik G; van Mark G; Bramlage P; Schmitt C; Luik A
    BMC Cardiovasc Disord; 2018 Apr; 18(1):71. PubMed ID: 29703158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimally interrupted novel oral anticoagulant versus uninterrupted vitamin K antagonist during atrial fibrillation ablation.
    De Heide J; Vroegh CJ; Bhagwandien RE; Wijchers SA; Szili-Torok T; Zijlstra F; Lenzen MJ; Yap SC
    J Interv Card Electrophysiol; 2018 Dec; 53(3):341-346. PubMed ID: 30074120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catheter ablation of left atrial arrhythmias on uninterrupted oral anticoagulation with vitamin K antagonists: What is the relationship between international normalized ratio, activated clotting time, and procedure-related complications?
    Kottmaier M; Bourier F; Semmler V; Telishevska M; Koch-Büttner K; Lennerz C; Lengauer S; Kornmayer M; Rousseva E; Brooks S; Brkic A; Grebmer C; Kolb C; Hessling G; Deisenhofer I; Reents T
    J Cardiovasc Electrophysiol; 2017 Dec; 28(12):1415-1422. PubMed ID: 28800176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.
    Cappato R; Marchlinski FE; Hohnloser SH; Naccarelli GV; Xiang J; Wilber DJ; Ma CS; Hess S; Wells DS; Juang G; Vijgen J; Hügl BJ; Balasubramaniam R; De Chillou C; Davies DW; Fields LE; Natale A;
    Eur Heart J; 2015 Jul; 36(28):1805-11. PubMed ID: 25975659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Uninterrupted Periprocedural Edoxaban in Patients Undergoing Catheter Ablation for Atrial Fibrillation　- The Prospective KYU-RABLE Study.
    Takahashi N; Mukai Y; Kimura T; Yamaguchi K; Matsumoto T; Origasa H; Okumura K;
    Circ J; 2019 Sep; 83(10):2017-2024. PubMed ID: 31511436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Intraprocedural Anticoagulation in Patients on Non-Vitamin K Antagonist Oral Anticoagulants Undergoing Catheter Ablation for Atrial Fibrillation: Understanding the Gaps in Evidence.
    Martin AC; Godier A; Narayanan K; Smadja DM; Marijon E
    Circulation; 2018 Aug; 138(6):627-633. PubMed ID: 30354610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillation.
    Naccarelli GV; Cappato R; Hohnloser SH; Marchlinski FE; Wilber DJ; Xiang J; Ma C; Hess S; Davies DW; Fields LE; Natale A;
    J Interv Card Electrophysiol; 2014 Nov; 41(2):107-16. PubMed ID: 25005452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of major bleeding events of uninterrupted non-vitamin K antagonist oral anticoagulants versus uninterrupted vitamin K antagonist during catheter ablation of atrial fibrillation: a meta-analysis of randomised controlled trials.
    Yang Q; Chen X; Zhai J; Dang Y
    Acta Cardiol; 2022 May; 77(3):257-263. PubMed ID: 33871328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of the safety and efficacy of using minimally interrupted novel oral anticoagulants in patients undergoing catheter ablation for atrial fibrillation.
    Mao YJ; Wang H; Huang PF
    J Interv Card Electrophysiol; 2021 Apr; 60(3):407-417. PubMed ID: 32361948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial.
    Ruff CT; Giugliano RP; Braunwald E; Mercuri M; Curt V; Betcher J; Grip L; Cange AL; Crompton AE; Murphy SA; Deenadayalu N; Antman EM
    J Am Coll Cardiol; 2014 Aug; 64(6):576-84. PubMed ID: 25104527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy.
    Zeljkovic I; Brusich S; Scherr D; Velagic V; Traykov V; Pernat A; Anic A; Szavits Nossan J; Jan M; Bakotic Z; Pezo Nikolic B; Radeljic V; Bojko A; Benko I; Manola S; Pavlovic N
    Clin Cardiol; 2021 Aug; 44(8):1177-1182. PubMed ID: 34196416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated Clotting Time Monitoring during Atrial Fibrillation Catheter Ablation: Does the Anticoagulant Matter?
    Martin AC; Kyheng M; Foissaud V; Duhamel A; Marijon E; Susen S; Godier A
    J Clin Med; 2020 Jan; 9(2):. PubMed ID: 32012701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower Major Bleeding Rates with Direct Oral Anticoagulants in Catheter Ablation of Atrial Fibrillation: an Updated Meta-analysis of Randomized Controlled Studies.
    Brunetti ND; Tricarico L; Tilz RR; Heeger CH; De Gennaro L; Correale M; Ieva R; Di Biase M; Rillig A; Metzner A; Santoro F
    Cardiovasc Drugs Ther; 2020 Apr; 34(2):209-214. PubMed ID: 32080786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Satisfaction and Convenience for Patients With Atrial Fibrillation on Edoxaban or Vitamin K Antagonists After Transcatheter Aortic Valve Replacement: A Post Hoc Analysis from the ENVISAGE-TAVI AF Trial.
    Hengstenberg C; Van Mieghem NM; Wang R; Ye X; Shi L; Guo S; Chen C; Jin J; Ye X; Dangas G; Unverdorben M
    Am J Cardiol; 2023 Dec; 209():212-219. PubMed ID: 37848174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.